Drug Research
UCB, ConfometRx sign drug discovery research deal
Belgium-based biopharmaceutical company UCB has signed a research deal with ConfometRx for the discovery of new drugs. Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor...
Drug Research
Dr. Reddy’s introduces Desloratadine ODT in US
Dr. Reddy's Laboratories has received the FDA approval and introduced Desloratadine orally disintegrating tablets (ODT) in 2.5mg and 5mg strengths in the US. Desloratadine ODT is a generic equivalent to Clarinex Reditabs (desloratadine), which...
Drug Research
Stellar Biotechnologies develops aquaculture system for KLH manufacturing
Stellar Biotechnologies has developed a controlled, commercial-scale aquaculture system for fully sustainable Keyhole Limpet Hemocyanin (KLH) manufacturing. The land-based aquaculture system is designed to support multiple generations of all stages of Megathura crenulata's life...
Drug Research
Synthon opens new GMP antibody-drug conjugate production facility in Nijmegen
Synthon Biopharmaceuticals has opened a GMP antibody-drug conjugate (ADC) production facility in Nijmegen. The Nijmegen facility will produce ADCs, which combine specific anti-cancer antibody or antibody fragment to an anti-cancer therapeutic, required for Phase...
Drug Research
Paladin introduces grass pollen allergy medication in Canada
Specialty pharmaceutical company Paladin Labs has introduced first allergen immunotherapy tablet, Oralair, against grass pollen allergies in Canada. The sublingual once daily medication should be administered from four months prior to the onset of...
Drug Research
Aptar Pharma names Jean-Marc Pardonge as prescription division new president
Aptar Pharma, a subsidiary of Aptargroup, has named Jean-Marc Pardonge as the new president for the company's prescription division. The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices. In...
Drug Research
FDA approves ThromboGenics vitreomacular adhesion therapy
The USFDA has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). The approval was based on the Phase III trial data which demonstrated that Jetrea is superior to placebo for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
